Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

UNIVERSITY OF NORTH CAROLINA HOSPITALS

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1989-01-01

Employees: -

Market Cap: -

Website: http://www.unc.edu/interactive-tour/unc-hospitals/

Clinical Trials

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Phase 1

Recruiting

Conditions: Relapse
Resistant Cancer
Breast Cancer
Triple Negative Breast Cancer

Interventions: Biological: iC9-CAR.B7-H3 T Cell Therapy
Drug: cyclophosphamide
Drug: fludarabine

First Posted Date: 2024-04-04

Last Posted Date: 2025-03-18

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 42

Registration Number: NCT06347068

Locations: 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Phase 2

Suspended

Conditions: Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Autologous Stem Cell Transplantation

Interventions: Biological: Daratumumab
Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2024-04-04

Last Posted Date: 2025-06-18

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 39

Registration Number: NCT06348147

Locations: 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Phase 1

Recruiting

Conditions: Ovary Neoplasm
Epithelial Ovarian Cancer
Ovarian Cancer
Recurrent

Interventions: Biological: iC9-CAR.B7-H3 T cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2024-03-12

Last Posted Date: 2024-10-26

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 27

Registration Number: NCT06305299

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

UNC Metastatic Cancer Radiation Therapy Registry

Recruiting

Conditions: Metastatic Cancer
Cancer

First Posted Date: 2024-03-12

Last Posted Date: 2025-05-01

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 2000

Registration Number: NCT06306924

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States

DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

Not Applicable

Recruiting

Conditions: Blood Cancers
Leukemia
Multiple Myeloma
Hematologic Malignancies
Lymphoma

First Posted Date: 2024-03-06

Last Posted Date: 2025-01-27

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 500

Registration Number: NCT06296368

Locations: 🇺🇸
Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States

Sparing Parotid Ducts Via MRI Sialography for Reduced Patient Reported Xerostomia

Not Applicable

Not yet recruiting

Conditions: Head and Neck Cancer
Oropharynx Cancer
Xerostomia

First Posted Date: 2024-02-26

Last Posted Date: 2025-06-04

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 98

Registration Number: NCT06276946

Locations: 🇺🇸
University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill, North Carolina, United States

Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya

Phase 1

Not yet recruiting

Conditions: Cervix; Intraepithelial Neoplasia, Grade II
Cervix Cancer
Cervix; Intraepithelial Neoplasia, Grade I
Cervix Intraepithelial Neoplasia Grade 3

Interventions: Drug: Artesunate pessary
Diagnostic Test: blood draws for pharmacokinetics of the study drug

First Posted Date: 2024-02-16

Last Posted Date: 2024-07-10

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 16

Registration Number: NCT06263582

Locations: 🇰🇪
Lumumba Sub-County Hospital, Kisumu, Kenya

Promoting CT Engagement for Pancreatic Cancer With App

Not Applicable

Recruiting

Conditions: Pancreas Cancer

First Posted Date: 2024-02-09

Last Posted Date: 2025-05-13

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 26

Registration Number: NCT06252545

Locations: 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸
Medical College Of Wisconsin, Milwaukee, Wisconsin, United States

Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer Survivors

Not Applicable

Active, not recruiting

Conditions: Physical Activity
Cancer
Cancer Survivorship
Mental Health
Obesity

First Posted Date: 2023-12-15

Last Posted Date: 2025-05-30

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 63

Registration Number: NCT06171945

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States

Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya

Phase 1

Recruiting

Conditions: Cervix Neoplasm
Precancerous Conditions
Cervix Cancer
Cervical Precancer

Interventions: Drug: Artesunate pessary
Procedure: Colposcopy

First Posted Date: 2023-12-11

Last Posted Date: 2025-04-15

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT06165614

Locations: 🇰🇪
Lumumba Sub-County Hospital, Kisumu, Kenya

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy